Literature DB >> 33939048

Thyroid Lobectomy for Low-Risk Papillary Thyroid Cancer: A National Survey of Low- and High-Volume Surgeons.

Alexandria D McDow1, Megan C Saucke2, Nicholas A Marka2, Kristin L Long2, Susan C Pitt2.   

Abstract

BACKGROUND: The 2015 American Thyroid Association guidelines endorsed lobectomy for patients with low-risk papillary thyroid cancer (PTC) measuring 1-4 cm. Attitudes about the use of lobectomy for these patients are lacking, particularly from low-volume surgeons who perform the majority of thyroidectomies in the US.
METHODS: A survey was mailed to 1000 surgeons stratified by specialty (500 general surgeons and 500 otolaryngologists) registered with the American Medical Association, to evaluate beliefs and practices about the extent of surgery for low-risk PTC. Comparisons examined differences by surgeon volume.
RESULTS: Of 320 respondents who have performed thyroidectomy since 2015 (150 general surgeons, 170 otolaryngologists), 206 (64.4%) were low volume (< 26 thyroidectomies/year). The proportion of surgeons recommending lobectomy for low-risk PTC measuring 1.1 to < 4 cm ranged from 43.1 to 2.6%. High-volume surgeons recommended lobectomy more frequently for PTC measuring 1.1-3 cm, although this was not statistically significant. Thirty-three percent of respondents believed lobectomy is underused for low-risk PTC, while 10.0% believed it is overused. Additionally, 19.6% of respondents believed recurrence is more likely after lobectomy than total thyroidectomy, and 3.3% believed mortality is higher. Few believed quality of life is better after lobectomy (12.3%). Low-volume surgeons were less likely to be aware guidelines support lobectomy for low-risk PTC 1-4 cm (p < 0.001) and less likely to use clinical practice guidelines (p = 0.004).
CONCLUSIONS: Most surgeons do not support lobectomy for patients with low-risk PTC > 1 cm. Awareness of guidelines and concerns about increased risk of recurrence after lobectomy may drive surgeons' preference for total thyroidectomy.

Entities:  

Year:  2021        PMID: 33939048     DOI: 10.1245/s10434-021-09898-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  1 in total

1.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ASSOCIAZIONE MEDICI ENDOCRINOLOGI MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND MANAGEMENT OF THYROID NODULES--2016 UPDATE.

Authors:  Hossein Gharib; Enrico Papini; Jeffrey R Garber; Daniel S Duick; R Mack Harrell; Laszlo Hegedüs; Ralf Paschke; Roberto Valcavi; Paolo Vitti
Journal:  Endocr Pract       Date:  2016-05       Impact factor: 3.443

  1 in total
  4 in total

Review 1.  Towards De-Implementation of low-value thyroid care in older adults.

Authors:  Jennifer M Perkins; Maria Papaleontiou
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2022-07-22       Impact factor: 3.626

2.  Trends in the Management of Localized Papillary Thyroid Carcinoma in the United States (2000-2018).

Authors:  Elisa Pasqual; Julie Ann Sosa; Yingxi Chen; Sara J Schonfeld; Amy Berrington de González; Cari M Kitahara
Journal:  Thyroid       Date:  2022-03-15       Impact factor: 6.506

3.  Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma - Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015.

Authors:  Agnieszka Czarniecka; Marcin Zeman; Grzegorz Wozniak; Adam Maciejewski; Ewa Stobiecka; Ewa Chmielik; Malgorzata Oczko-Wojciechowska; Jolanta Krajewska; Daria Handkiewicz-Junak; Barbara Jarzab
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-06       Impact factor: 5.555

4.  Endoscopic-assisted lateral neck dissection and open lateral neck dissection in the treatment of lateral neck lymph node metastasis in papillary thyroid carcinoma: A comparison of therapeutic effect.

Authors:  Tao Ma; Shuai Zhang; Dongmei Huang; Gang Zhang; Boyi Chen; Ning Zhang
Journal:  Pak J Med Sci       Date:  2022 Sep-Oct       Impact factor: 2.340

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.